Alkermes plc (ALKS)
NASDAQ: ALKS · IEX Real-Time Price · USD
24.19
-0.20 (-0.82%)
At close: Jul 2, 2024, 4:00 PM
24.08
-0.11 (-0.45%)
After-hours: Jul 2, 2024, 5:41 PM EDT
Alkermes Employees
Alkermes had 2,100 employees as of February 9, 2024. The number of employees decreased by 180 or -7.89% compared to the previous year.
Employees
2,100
Change (1Y)
-180
Growth (1Y)
-7.89%
Revenue / Employee
$821,991
Profits / Employee
$206,871
Market Cap
4.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 9, 2024 | 2,100 | -180 | -7.89% |
Feb 10, 2023 | 2,280 | 69 | 3.12% |
Feb 4, 2022 | 2,211 | -34 | -1.51% |
Feb 5, 2021 | 2,245 | 10 | 0.45% |
Feb 4, 2020 | 2,235 | -65 | -2.83% |
Feb 4, 2019 | 2,300 | 300 | 15.00% |
Feb 2, 2018 | 2,000 | 250 | 14.29% |
Feb 3, 2017 | 1,750 | 250 | 16.67% |
Feb 12, 2016 | 1,500 | 200 | 15.38% |
Feb 12, 2015 | 1,300 | 50 | 4.00% |
Feb 13, 2014 | 1,250 | 20 | 1.63% |
May 8, 2013 | 1,230 | 30 | 2.50% |
May 10, 2012 | 1,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
Integer Holdings | 10,500 |
RadNet | 7,872 |
Haemonetics | 3,657 |
Inspire Medical Systems | 1,011 |
ImmunityBio | 628 |
Merus | 229 |
Immunovant | 207 |
ALKS News
- 4 weeks ago - Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 - PRNewsWire
- 4 weeks ago - Alkermes to Participate in Two Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 - PRNewsWire
- 7 weeks ago - Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences - PRNewsWire
- 2 months ago - Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk - PRNewsWire
- 2 months ago - Alkermes plc Reports First Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 - PRNewsWire
- 2 months ago - Alkermes to Report First Quarter Financial Results on May 1, 2024 - PRNewsWire